STOCK MARKET BSE NSE

Hyderabad-based Hetero Drugs to produce 100 million Sputnik V vaccine doses per year

Hetero Biopharma, Russian Direct Investment Fund to start vaccine production in early 2021
 

Published: 28th November 2020 08:21 AM  |   Last Updated: 28th November 2020 08:24 AM   |  A+A-

Sputnik V, Russia covid-19 vaccine,

Sputnik V vaccine (File photo| AP)

By Express News Service

HYDERABAD: Hyderabad-based pharmaceutical company Hetero Drugs has reached an agreement with the Russian Direct Investment Fund (RDIF) to produce over 100 million doses per year of the RDIF’s Sputnik V Covid-19 vaccine in India. The agreement has been reached by Hetero Drugs through its biologics arm Hetero Biopharma. The two parties intend to start the production of Sputnik V at the start of 2021. 

“We believe that manufacturing the product (Sputnik V) locally is crucial to enable swift access to patients,’ said Hetero Labs Limited, Director of International Marketing, B Murali Krishna Reddy. It may be mentioned here that Dr Reddy’s Laboratories Ltd has received the approval from Drugs Controller General of India to conduct the Phase 2/3 clinical trials of the vaccine in India.

ALSO READ: Clear picture on vaccine by early 2021, says Union Health Minister Harsh Vardhan

In September this year, Dr Reddy’s and RDIF entered into a partnership to conduct clinical trials and distribution of the vaccine in India, as part of which RDIF will supply 100 million doses of the vaccine to Dr Reddy’s upon regulatory approval. 

RDIF CEO Kirill Dmitriev said: “We are delighted to announce the agreement between RDIF and Hetero that will pave the way for production of the highly effective Sputnik V vaccine on Indian soil. The vaccine’s interim clinical trial results show 95% efficacy on the 42nd day after the first dose. Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity.”



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp